- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07581457
Tranexamic Acid in Pediatric Idiopathic Scoliosis Surgery
Efficacy and Safety of Two Intravenous Tranexamic Acid Regimens Versus Placebo in Pediatric Idiopathic Scoliosis Surgery: A Randomized Double-Blind Trial
This study will evaluate whether tranexamic acid (TXA), a medication used to reduce bleeding, is effective and safe in children undergoing surgery for idiopathic scoliosis. Significant blood loss is common during this type of surgery and often requires blood transfusions.
Participants will be randomly assigned to one of three groups: (1) TXA given as an intravenous bolus followed by continuous infusion, (2) TXA given as two intravenous bolus doses, or (3) placebo (saline). Neither the patients nor the medical team will know which treatment is given.
The main goal is to compare how much blood is lost during and after surgery and whether TXA reduces the need for blood transfusions. The study will also assess safety, including the risk of side effects such as seizures or blood clots.
Patients will be followed for up to 30 days after surgery.
Aperçu de l'étude
Statut
Les conditions
Description détaillée
Posterior spinal fusion for adolescent idiopathic scoliosis is associated with significant intraoperative blood loss and frequent need for blood transfusion. Tranexamic acid (TXA) is an antifibrinolytic agent that reduces bleeding, but optimal dosing strategies in pediatric scoliosis surgery remain unclear.
This study is a prospective, randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of two intravenous TXA regimens compared with placebo in children undergoing surgical correction of idiopathic scoliosis.
Participants aged 10-18 years will be randomly assigned to receive either TXA or placebo during surgery. All patients will undergo standardized anesthesia, regional analgesia, and intraoperative neuromonitoring according to institutional protocols.
The primary objective is to assess the effect of TXA on perioperative blood loss. Secondary objectives include evaluation of transfusion requirements, laboratory parameters, and safety outcomes.
Patients will be followed for 30 days after surgery to assess postoperative outcomes and adverse events.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Malgorzata Reysner, MD PhD
- Numéro de téléphone: +48 61 831-01-22
- E-mail: mreysner@ump.edu.pl
Sauvegarde des contacts de l'étude
- Nom: Piotr Janusz, MD PhD
- E-mail: pjanusz@um.edu.pl
Lieux d'étude
-
-
-
Poznan, Pologne, 62-701
- Recrutement
- Poznan University of Medical Sciences
-
Contact:
- Malgorzata Reysner, M.D. Ph.D.
- Numéro de téléphone: +48 61 873 83 03
- E-mail: mreysner@ump.edu.pl
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Age 10 to 18 years
- Diagnosis of idiopathic scoliosis requiring surgical correction (posterior spinal fusion)
- American Society of Anesthesiologists (ASA) physical status I-II
- Written informed consent from parents or legal guardians and assent from the child
Exclusion Criteria:
- Congenital or acquired coagulopathy
- History of thromboembolic disease
- History of seizures or epilepsy
- Known hypersensitivity to tranexamic acid
- Renal insufficiency (estimated glomerular filtration rate < 60 mL/min/1.73 m²)
- Cardiac arrhythmias or cardiovascular disease requiring antiplatelet or anticoagulant therapy
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Quadruple
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: TXA Bolus + Infusion
Tranexamic acid administered intravenously as a 15 mg/kg bolus after induction of anesthesia, followed by continuous infusion at 1 mg/kg/h until the end of surgery. Maximum total dose not exceeding 2 g. All patients receive standardized anesthesia (TIVA with propofol and remifentanil), erector spinae plane block, and intraoperative neuromonitoring. |
Tranexamic acid administered intravenously as a 15 mg/kg bolus after induction of anesthesia, followed by continuous infusion at 1 mg/kg/h until the end of surgery.
Autres noms:
|
|
Comparateur placebo: Placebo
0.9% sodium chloride (saline) administered intravenously in the same volumes and timing as the active comparator groups (bolus and infusion). All patients receive standardized anesthesia (TIVA with propofol and remifentanil), erector spinae plane block, and intraoperative neuromonitoring. |
Intravenous administration of 0.9% sodium chloride solution used as placebo, matched in volume and timing to the active comparator groups.
Autres noms:
|
|
Expérimental: TXA Bolus Only
Tranexamic acid administered intravenously as two bolus doses: 10 mg/kg after induction of anesthesia and 10 mg/kg 120 minutes after surgical incision or at the beginning of rod placement (whichever occurs first). Maximum total dose not exceeding 2 g. All patients receive standardized anesthesia (TIVA with propofol and remifentanil), erector spinae plane block, and intraoperative neuromonitoring. |
Tranexamic acid administered intravenously as two bolus doses: 10 mg/kg after induction of anesthesia and 10 mg/kg 120 minutes after surgical incision or at the beginning of rod placement, whichever occurs first.
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Total Blood Loss
Délai: 24 hours postoperatively
|
Total blood loss expressed in ml/kg |
24 hours postoperatively
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Total Volume of Blood Transfusion
Délai: 24 hours postoperatively
|
Total volume of transfused blood products (ml/kg) administered intraoperatively and within the first 24 hours postoperatively. |
24 hours postoperatively
|
|
Hemoglobin Level
Délai: immediately after surgery (0 hours)
|
Hemoglobin concentration measured in g/dL |
immediately after surgery (0 hours)
|
|
Hemoglobin Level
Délai: 24 hours postoperatively
|
Hemoglobin concentration measured in g/dL |
24 hours postoperatively
|
|
Hematocrit Level
Délai: immediately after surgery (0 hours)
|
Hematocrit value (%) |
immediately after surgery (0 hours)
|
|
Hematocrit Level
Délai: 24 hours postoperatively
|
Hematocrit value (%) |
24 hours postoperatively
|
|
D-dimer Level
Délai: 24 hours postoperatively
|
Plasma D-dimer concentration measured in mg/L |
24 hours postoperatively
|
|
Fibrinogen Level
Délai: 24 hours postoperatively
|
Plasma fibrinogen concentration measured in g/L |
24 hours postoperatively
|
|
Prothrombin Time
Délai: 24 hours postoperatively
|
Prothrombin time measured in seconds |
24 hours postoperatively
|
|
Activated Partial Thromboplastin Time
Délai: 24 hours postoperatively
|
Activated partial thromboplastin time measured in seconds |
24 hours postoperatively
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chaise d'étude: Małgorzata Reysner, MD PhD, Poznan University of Medical Sciences
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies osseuses
- Maladies musculo-squelettiques
- Maladies de la colonne vertébrale
- Courbures vertébrales
- Scoliose
- Produits chimiques organiques
- Préparations pharmaceutiques
- Acides carboxyliques
- Produits chimiques inorganiques
- Composés de chlore
- Solutions cristalloïdes
- Solutions isotoniques
- Solutions
- Acides, carbocyclique
- Acides cyclohexanecarboxyliques
- Composés de sodium
- Chlorures
- Acide chlorhydrique
- Acide tranexamique
- Solution saline
- Chlorure de sodium
Autres numéros d'identification d'étude
- 2/2026
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Individual participant data (IPD) underlying the results reported in this study, after de-identification, will be shared. This includes demographic data, perioperative variables, laboratory results, and outcome measures. Supporting documents such as the study protocol and statistical analysis plan will also be available.
Délai de partage IPD
Data will be available beginning 6 months after publication of the primary results and ending 5 years after publication.
Critères d'accès au partage IPD
Data will be shared with researchers who provide a methodologically sound proposal. Proposals should be directed to the principal investigator. Data access will be granted following approval by the study investigators and after signing a data access agreement.
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- SÈVE
- CIF
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .